Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Opsens Inc (OPS.TO)

Opsens Inc (OPS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 335,470
  • Shares Outstanding, K 115,679
  • Annual Sales, $ 48,347 K
  • Annual Income, $ -12,402 K
  • 60-Month Beta -0.44
  • Price/Sales 6.79
  • Price/Cash Flow N/A
  • Price/Book 9.92
Trade OPS.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings $-0.01 on N/A
  • Latest Earnings Date 01/11/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/23
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.84 +2.11%
on 11/22/23
2.90 unch
on 12/13/23
+0.05 (+1.75%)
since 11/13/23
3-Month
1.60 +81.25%
on 09/27/23
2.90 unch
on 12/13/23
+1.03 (+55.08%)
since 09/13/23
52-Week
1.36 +113.24%
on 05/19/23
2.90 unch
on 12/13/23
+1.00 (+52.63%)
since 12/13/22

Most Recent Stories

More News
HAEMONETICS COMPLETES ACQUISITION OF OPSENS

/CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions...

OPSSF : 2.1389 (+0.64%)
HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
Stocks in play: OpSens Inc.

Announces that the Superior Court of Québec issued a final order today in connection with the previously ...

HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS

/CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions...

OPSSF : 2.1389 (+0.64%)
HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS

/CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions...

OPSSF : 2.1389 (+0.64%)
HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED

All amounts in this press release are in Canadian dollars. Clearance under both the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the...

OPSSF : 2.1389 (+0.64%)
HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS

/CNW/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on...

OPSSF : 2.1389 (+0.64%)
OPS.TO : 2.90 (unch)
INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION

All amounts in this press release are in Canadian dollars. Leading independent proxy advisor says cash offer provides meaningful 50.3% premium to OpSens Inc.'s...

OPSSF : 2.1389 (+0.64%)
HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
OPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS

/CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF) announces that the Québec Superior Court (the "Court") issued an interim order...

OPSSF : 2.1389 (+0.64%)
HAE : 81.24 (-2.66%)
OPS.TO : 2.90 (unch)
OPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE

/CNW/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on...

MDT : 79.48 (+0.37%)
OPSSF : 2.1389 (+0.64%)
OPS.TO : 2.90 (unch)
OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 - 26, 2023

/CNW/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on...

OPSSF : 2.1389 (+0.64%)
OPS.TO : 2.90 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 2.90
2nd Resistance Point 2.90
1st Resistance Point 2.90
Last Price 2.90
1st Support Level 2.90
2nd Support Level 2.90
3rd Support Level 2.90

See More

52-Week High 2.90
Last Price 2.90
Fibonacci 61.8% 2.31
Fibonacci 50% 2.13
Fibonacci 38.2% 1.95
52-Week Low 1.36

See More

Business Summary

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. It operates in two segments that are Medical and Industrial....

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar